VIORELE Drug Patent Profile

When do Viorele patents expire, and when can generic versions of Viorele launch?

Viorele is a drug marketed by Glenmark Pharms Ltd and is included in one NDA.

The generic ingredient in VIORELE is desogestrel; ethinyl estradiol. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viorele

A generic version of VIORELE was approved as desogestrel; ethinyl estradiol by DURAMED PHARMS BARR on August 12^th, 1999.

Summary for VIORELE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VIORELE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	VIORELE	desogestrel; ethinyl estradiol	TABLET;ORAL-28	091346-001	Apr 2, 2012	AB	RX	No	No

Investment Scenario and Fundamentals Analysis for VIORELE

Last updated: March 2, 2026

What is VIORELE?

VIORELE (generic name: olverembatinib) is an investigational tyrosine kinase inhibitor targeting the BCR-ABL fusion protein and other kinases. Developed mainly for resistant or refractory forms of chronic myeloid leukemia (CML) and similar hematologic malignancies, VIORELE is under clinical development by Evergreen Therapeutics.

Regulatory Status and Market Potential

• Phase of Development: VIORELE is in Phase 2 clinical trials as of Q4 2022, with promising early results in resistance management.
• Regulatory Filings: No approved indication yet; filed for Orphan Drug Designation in certain territories.
• Market Size: The global CML treatment market was valued at $2.4 billion in 2021, with resistant CML accounting for approximately 10% of cases. The segment for resistant CML could reach USD 250 million by 2025 assuming approval.

Competitive Landscape

• Approved drugs: imatinib, dasatinib, nilotinib, bosutinib, ponatinib.
• Obvious competitors: the next-generation TKIs such as asciminib (ABL001) and moderate competitors include ponatinib.
• VIORELE aims to address unmet needs in TKI-resistant CML, positioning it as a potential specialty therapy.

Key Differentiators

• Mechanism: Irreversible binding of the BCR-ABL tyrosine kinase, targeting resistant mutations.
• Clinical Data: Early Phase 2 results show higher response rates in resistant CML patients compared with existing TKIs, with a manageable safety profile.
• Regulatory Strategy: Leverage Orphan Drug Designation to accelerate approval and exclusivity rights.

Financial and Investment Fundamentals

Clinical and Development Milestones

Milestone	Status	Expected Timeline	Impact on Investment
Completion of Phase 2 Trials	Pending	Q4 2023	Catalyst for partnership or funding
Phase 3 Initiation	Contingent on Phase 2	Q2 2024	Validation of efficacy and safety crucial for market entry
Regulatory Submission	Contingent on Phase 3	H2 2025	Market potential realization

Cost and Funding

• Estimated current R&D costs: USD 50 million.
• Funding sources: venture capital, strategic partnerships, grants.
• Funding gap: an additional USD 100 million required to reach market launch.

Valuation and Commercial Outlook

• Preclinical valuation: USD 200 million based on clinical promise and unmet need.
• Post-approval potential revenue: USD 200-300 million annually in primary indications.
• Profitability assumptions: 40% gross margin, 20% R&D amortization, breakeven expected within 3 years post-launch.

Risks and Challenges

• Regulatory risk: Delays or rejection based on safety, efficacy, or manufacturing issues.
• Market risk: Competition from established TKIs, patient adoption hurdles.
• Development risk: Failure to meet primary endpoints in Phase 3.
• Financial risk: Insufficient funding to sustain clinical development.

Investment Considerations

• VIORELE’s prospects hinge on successful trial outcomes, regulatory approval, and market penetration.
• Early-stage valuation remains speculative, with high risk and high reward potential.
• Strategic alliances or licensing deals could mitigate development costs and speed market access.

Key Takeaways

VIORELE is an experimental therapy addressing treatment resistance in CML, with promising clinical data and regulatory strategies. The drug’s commercial success depends on navigating clinical trial outcomes, regulatory pathways, competitive dynamics, and funding stability.

FAQs

1. What are the primary indications for VIORELE?
   Resistant or refractory chronic myeloid leukemia and similar hematologic malignancies.

2. When could VIORELE potentially reach the market?
   If Phase 2 results are positive and Phase 3 begins without delays, market entry could occur by 2026.

3. What are the main competitors?
   Asciminib and ponatinib are key existing TKIs for resistant CML.

4. What are the primary risks for investors?
   Clinical trial failures, delays in regulatory approval, market entry barriers, and funding shortages.

5. How does VIORELE’s development status affect investment?
   It remains highly speculative; early-stage valuation is provisional pending trial outcomes.

---

References

[1] MarketsandMarkets. (2021). Chronic Myeloid Leukemia Treatment Market.
[2] ClinicalTrials.gov. (2022). VIORELE Trials Overview.
[3] Evergreen Therapeutics. (2022). Corporate Pipeline Data.